Kymera Therapeutics officer plans $3.35M share sale

The notice lists the planned sale’s aggregate market value at $3,353,700 and names UBS Financial Services, Inc. as broker.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) is named in a notice that Nello Mainolfi, identified as an officer and director, intends to sell 30,000 common shares through UBS Financial Services, Inc., with an approximate sale date of October 1, 2026. The notice lists an aggregate market value of $3,353,700. The shares are listed as acquired from the issuer through exercise of stock options on October 1, 2026, with cash payment.

Key Figures

Common shares proposed for sale: 30,000 shares Aggregate market value: $3,353,700 Shares outstanding: 83,150,618 shares +4 more

7 metrics

Common shares proposed for sale 30,000 shares Approximate sale date October 1, 2026

Aggregate market value $3,353,700 Proposed sale

Shares outstanding 83,150,618 shares Listed in the securities information

Common shares sold 80,000 shares July 1, 2026

Gross proceeds $9,223,529.00 Sale on July 1, 2026

Common shares sold 50,000 shares July 7, 2026

Gross proceeds $5,950,000.00 Sale on July 7, 2026

Key Terms

Rule 144, exercise of stock options, aggregate market value, gross proceeds

4 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

exercise of stock options financial

"Exercise of stock options"

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

gross proceeds financial

"Securities Sold During The Past 3 Months"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KYMR shares does Nello Mainolfi plan to sell?

Nello Mainolfi’s notice lists 30,000 Kymera common shares for sale, with an approximate sale date of October 1, 2026, through UBS Financial Services, Inc. The listed aggregate market value is $3,353,700.

What were Nello Mainolfi’s prior KYMR share sales?

The notice lists a sale of 80,000 common shares on July 1, 2026, for gross proceeds of $9,223,529.00, and a sale of 50,000 common shares on July 7, 2026, for gross proceeds of $5,950,000.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:10 PM Accepted by SEC EDGAR 10/01/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001821189
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kymera Therapeutics, Inc.
SEC File Number	001-39460
Address of Issuer	500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MASSACHUSETTS 02472
Phone	857-285-5314
Name of Person for Whose Account the Securities are To Be Sold	Mainolfi Nello
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	30000	3353700.00	83150618	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2026	Exercise of stock options	Issuer			30000	10/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Nello Mainolfi 500 NORTH BEACON STREET 4TH FLOOR WATERTOWN MA 02472	Common	07/01/2026	80000	9223529.00
Nello Mainolfi 500 NORTH BEACON STREET 4TH FLOOR WATERTOWN MA 02472	Common	07/07/2026	50000	5950000.00

144: Remarks and Signature

Remarks
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Nello Mainolfi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)